{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58","upperLimit":"86","value":"70"},{"groupId":"OG001","lowerLimit":"4","upperLimit":"36","value":"12"},{"groupId":"OG002","lowerLimit":"51","upperLimit":"80","value":"64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"47"}],"units":"Participants"}],"description":"irPFS rate is defined as the percentage of patients with disease progression (irPD or relapse from irCR as assessed using irRC criteria) or death due to any cause at 28 weeks. Per irRC criteria, Complete Response (irCR) is the disappearance of all target lesions, Partial Response (irPR) is a decrease in tumor burden by 50% or greater by a consecutive assessment at least 4 weeks after first documentation, Stable Disease (irSD) is the failure to meet criteria for irCR or irPR (in absence of irPD), Progressive Disease (irPD) is at least 25% increase in tumor burden relative to nadir. Estimation based on the Kaplan-Meier curve.","dispersionType":"95% Confidence Interval","groups":[{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG000","title":"Cohort A: MSI Positive Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG001","title":"Cohort B: MSI Negative Colorectal Cancer"},{"description":"MK-3475: MK-3475 10 mg/kg every 14 days","id":"OG002","title":"Cohort C: MSI Positive Non-Colorectal Cancer"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"28 weeks","title":"Immune-related Progression Free Survival (irPFS) at 28 Weeks in MSI Positive and Negative Solid Tumor Malignancies Using Immune Related Response Criteria (irRC)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}